Uric Acid and Arterial Stiffness

References

• Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14. doi:10.1016/j.ijcard.2015.08.109
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi:10.1056/NEJMra0800885
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3:208–220. doi:10.1159/000355405
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA. Raised concentrations of serum creatinine and uric acid and the risks of mortality and cardiovascular disease. Cardiovasc Rev Rep. 2002;23:393–399.
   Google Scholar
• Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069–1074. doi:10.1161/01.hyp.37.4.1069
   PubMed Web of Science ®Google Scholar
• Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–1551. doi:10.1001/archinte.164.14.1546
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072–1078. doi:10.1161/01.hyp.36.6.1072
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Azaouridis K, Stefanidis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–1327. doi:10.1093/eurheartj/ehq024
   PubMed Web of Science ®Google Scholar
• Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54:1328–1336. doi:10.1161/HYPERTENSIONAHA.109.137653
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–2605. doi:10.1093/eurheartj/ehl254
   PubMed Web of Science ®Google Scholar
• Sun C-K. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integrated Blood Pressure Control. 2013;6:27–38. doi:10.2147/IBPC.S34423
   PubMedGoogle Scholar
• El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. J Adv Res. 2017;8:487–493. doi:10.1016/j.jare.2017.03.003
   PubMed Web of Science ®Google Scholar
• Backer BF. Towards the physiological function of uric acid. Review. Free Radic Biol Med. 1993;14(6):615–631. doi:10.1016/0891-5849(93)90143-i
   PubMed Web of Science ®Google Scholar
• Glantzounis GK, Tsimoyannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145–4151. doi:10.2174/138161205774913255
   PubMed Web of Science ®Google Scholar
• Kurra V, Eraranta A, Jolma P, et al. Hyperuricemia, oxidative stress and carotid artery tone in experimental renal insufficiency. Am J Hypertens. 2009;22:964–970. doi:10.1038/ajh.2009.109
   PubMed Web of Science ®Google Scholar
• Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond). 2003;105:425–430. doi:10.1042/CS20030149
   PubMed Web of Science ®Google Scholar
• Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001;38:365–371. doi:10.1097/00005344-200109000-00005
   PubMed Web of Science ®Google Scholar
• Waring WS, McNight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smoking. Diabetes. 2006;55:3127–3132. doi:10.2337/db06-0283
   PubMed Web of Science ®Google Scholar
• Sugihara S, Hisatome I, Kuwabara M, et al. Depletion of uric acid due to SCL22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia. Circ J. 2015;79(5):1125–1132. doi:10.1253/circj.CJ-14-1267
   PubMed Web of Science ®Google Scholar
• Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res. 2003;44:512–521. doi:10.1194/jlr.M200407-JLR200
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Renal Physiol. 2008;295:F1134– F1141. doi:10.1152/ajprenal.00104.2008
   PubMed Web of Science ®Google Scholar
• Xie H, Sun J, Chen Y, Zong M, Li S, Wang Y. EGCG attenuates uric acid-induced inflammatory and oxidative stress responses by medicating the NOTCH pathway. Oxid Med Cell Longev. 2015;2015:214836. doi:10.1155/2015/214836
   PubMed Web of Science ®Google Scholar
• Choi Y-J, Yoon Y, Lee K-Y. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197–3204. doi:10.1096/fj.13-247148
   PubMed Web of Science ®Google Scholar
• Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008;295:C1183–C1190. doi:10.1152/ajpcell.00075.2008
   PubMed Web of Science ®Google Scholar
• Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17:656–669. doi:10.2741/3950
   PubMed Web of Science ®Google Scholar
• Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide. 2007;16:266–273. doi:10.1016/j.niox.2006.10.008
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–1742. doi:10.1111/j.1523-1755.2005.00273.x
   PubMed Web of Science ®Google Scholar
• Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular rennin-angiotensin system. J Hypertens. 2008;26:269–275. doi:10.1097/HJH.0b013e3282f240bf
   PubMed Web of Science ®Google Scholar
• Drüppel V, Kusche-Vihrog K, Grossmann C, et al. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB J. 2013;27:3652–3659. doi:10.1096/fj.13-228312
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr. Systolic hypertension, arterial stiffness, and vascular damage: role of the renin-angiotensin system. Blood Press Monit. 2000;5(Suppl 2):S7–S11. doi:10.1097/01.hco.0000126581.89648.10
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286–1292. doi:10.1056/NEJM199411103311907
   PubMed Web of Science ®Google Scholar
• Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–943. doi:10.1161/01.ATV.0000160548.78317.29
   PubMed Web of Science ®Google Scholar
• Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732. doi:10.1038/348730a0
   PubMed Web of Science ®Google Scholar
• Du Plooy CS, Martha Cornelia Mels C, Huisman HC, Kruger R. The association of endothelin-1 with markers of arterial stiffness in black South African women: the SABPA Study. J Amino Acids. 2015;2015:8. doi:10.1155/2015/481517
   Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287–1293. doi:10.1161/01.HYP.0000072820.07472.3B
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–2897. doi:10.1097/01.asn.0000034910.58454.fd
   PubMed Web of Science ®Google Scholar
• Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604–8608.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. doi:10.1038/sigtrans.2017.23
   PubMed Web of Science ®Google Scholar
• Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–3562. doi:10.1681/ASN.2005050572
   PubMed Web of Science ®Google Scholar
• Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood. 1997;89:577–582. doi:10.1182/blood.V89.2.577
   PubMed Web of Science ®Google Scholar
• Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53(2):258–261. doi:10.3349/ymj.2012.53.2.258
   PubMed Web of Science ®Google Scholar
• Ko J, Kang H-J, Kim D-A, et al. Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding. FASEB J. 2019;25:fj201901148R. doi:10.1096/fj.201901148R
   Web of Science ®Google Scholar
• Yamanaka H, Osaka M, Takayama M, Munakata K, Nejima J, Katayama M. Age-adjusted level of circulating elastin as a cardiovascular risk factor in medical check-up individuals. J Cardiovasc Med (Hagerstown). 2014;15:364–370. doi:10.2459/JCM.0b013e328360940b
   PubMed Web of Science ®Google Scholar
• Kushiyama A, Nakatsu Y, Matsunaga Y, et al. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. Mediators Inlamm. 2016;2016. doi:10.1155/2016/8603164
   Google Scholar
• Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension. 2018;72:582–584. doi:10.1161/HYPERTENSIONAHA.118.11496
   PubMed Web of Science ®Google Scholar
• Mishima M, Hamada T, Maharani N, et al. Effects of uric acid on the NO production of HUVECs and its restoration by urate lowering agents. Drug Res (STUTTG.). 2016;66:270–274. doi:10.1055/s-0035-1569405
   PubMedGoogle Scholar
• Gicquel T, Robert S, Loyer P, et al. IL-1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages. FASEB J. 2015;29:4162–4173. doi:10.1096/fj.14-267393
   PubMed Web of Science ®Google Scholar
• Moriwaki Y, Yamamoto T, Suda M, et al. Purification and immunohistochemical tissue localization of human xanthine oxidase. Biochim Biophys Acta. 1993;1164(3):327–330. doi:10.1016/0167-4838(93)90266-t
   PubMed Web of Science ®Google Scholar
• Nomura J, Busso N, Yves A, et al. Xantine oxidase inhibition by fenbuxostat attenuates experimental atherosclerosis in mice. Sci Reports. 2014;4:4554. doi:10.1038/srep04554
   PubMed Web of Science ®Google Scholar
• Lastra G, Manrique C, Jia G, et al. Xanthine oxidase inhibition protects against Western diet-induced aortic stiffness and impaired vasorelaxation in female mice. Am J Physiol Regul Integr Comp Physiol. 2017;313:R67–R77. doi:10.1152/ajpregu.00483.2016
   PubMed Web of Science ®Google Scholar
• Aroor AR, Jiaa G, Habibia J, et al. Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism. 2017;74:32–40. doi:10.1016/j.metabol.2017.06.006
   PubMed Web of Science ®Google Scholar
• Mehta T, Nuccio E, McFan K, Madero M, Sarnak MJ, Jala D. Association of uric acid with vascular stiffness in the Framingham study. Am J Hypertens. 2015;28(7):877–883. doi:10.1093/ajh/hpu253
   PubMed Web of Science ®Google Scholar
• Bae JS, Shin DH, Park PS, et al. The impact of serum uric acid level on arterial stiffness and carotid atherosclerosis: the Korean Multi-Rural Communities Cohort study. Atherosclerosis. 2013;231(1):145–151. doi:10.1016/j.atherosclerosis.2013.08.017
   PubMed Web of Science ®Google Scholar
• Liu H, Liu J, Zhao H, Zhou Y, Li L, Wang H, For the BEST Research Group. Relationship between serum uric acid and vascular function and structure markers and gender difference in a real-world population of China-From Beijing Vascular Disease Patients Evaluation Study (BEST) study. J Atheroscler Thromb. 2018;25:254–261. doi:10.5551/jat.39685.
   PubMed Web of Science ®Google Scholar
• Nagayama D, Yamaguchi T, Saiki A, et al. High serum uric acid is associated with increased cardio-ankle vascular index (CAVI) in healthy Japanese subjects: a cross-sectional study. Atherosclerosis. 2015;239(1):163–168. doi:10.1016/j.atherosclerosis.2015.01.011
   PubMed Web of Science ®Google Scholar
• Hwang J, Hwang JH, Chung SM, Kwon M-J, Ahn JK. Association between serum uric acid and arterial stiffness in a low-risk, middle-aged, large Korean population A cross-sectional study. Medicine. 2018;97:36. doi:10.1097/MD.0000000000012086
   Web of Science ®Google Scholar
• Choi HY, Kim S-H, Choi AR, et al. Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening Korean population. PLoS One. 2017;12(6):e0180406. doi:10.1371/journal.pone.0180406
   PubMed Web of Science ®Google Scholar
• Zheng X, Wei Q, Long J, et al. Gender-specific association of serum uric acid levels and cardio-ankle vascular index in Chinese adults. Lipids Health Dis. 2018;17:80. doi:10.1186/s12944-018-0712-x
   PubMed Web of Science ®Google Scholar
• Bian S, Guo H, Ye P, Luo L, Wu H, Xia W. Serum uric acid level and diverse impacts on regional arterial stiffness and wave reflection. Iranian J Publ Health. 2012;41(8):33–41.
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis. 2007;192:131–137. doi:10.1016/j.atherosclerosis.2006.04.016
   PubMed Web of Science ®Google Scholar
• Fang J-I, Wu J-S, Yang Y-C, Wang R-H, Lu F-H, Chang C-J. High uric acid level associated with increased arterial stiffness in apparently healthy women. Atherosclerosis. 2014;236(2):389–393. doi:10.1016/j.atherosclerosis.2014.07.024
   PubMed Web of Science ®Google Scholar
• Chou P, Lin KC, Lin HY, Tsai ST. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol. 2001;28(3):571–576.
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–1049. doi:10.1111/j.1523-1755.2004.00484.x
   PubMed Web of Science ®Google Scholar
• Heo SH, Lee SH. High levels of serum uric acid are associated with silent brain infarction. J Neurol Sci. 2010;297:6–10. doi:10.1016/j.jns.2010.07.007
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62:170–180. doi:10.1002/acr.20065
   PubMed Web of Science ®Google Scholar
• Chen X, Li Y, Sheng C-S, Huang Q-F, Zheng Y, Wang J-G. Association of serum uric acid with aortic stiffness and pressure in a Chinese workplace setting. Am J Hypertens. 2010;23(4):387–392. doi:10.1038/ajh.2009.277
   PubMed Web of Science ®Google Scholar
• Shin JY, Lee HR, Shim JY. Significance of high-normal serum uric acid level as a risk factor for arterial stiffness in healthy Korean men. Vasc Med. 2012;17(1):37–43. doi:10.1177/1358863X11434197
   PubMed Web of Science ®Google Scholar
• Baena CP, Lotufo PA, Mill JG, et al. Serum uric acid and pulse wave velocity among healthy adults: baseline data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Am J Hypertens. 2015;28:966–970. doi:10.1093/ajh/hpu298
   PubMed Web of Science ®Google Scholar
• Liang J, Li Y, Zhou N, et al. Synergistic effects of serum uric acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in Chinese study. PLoS One. 2012;7(12):e51101. doi:10.1371/journal.pone.0051101
   PubMed Web of Science ®Google Scholar
• Sull JW, Koh EN, Cho SK, Bae H-J, Jee SH. Association of uric acid levels with arterial stiffness in Korean women and non-smoking men. Biomed Sci Letters. 2017;23(3):201–207. doi:10.15616/BSL.2017.23.3.201
   Google Scholar
• Cicero AFG, Salvi P, D’Addato S, Rosticci M, Borghi C, for the Brisighella Heart Study group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64. doi:10.1097/HJH.0b013e328365b916
   PubMed Web of Science ®Google Scholar
• Fu S, Luo L, Ye P, Xiao W. Multimarker analysis for new biomarkers in relation to central arterial stiffness and hemodynamics in a Chinese community-dwelling population. Angiology. 2015;66:950–956. doi:10.1177/0003319715573910
   PubMed Web of Science ®Google Scholar
• Li Y, Lu J, Wu X, Yang C. Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. Angiology. 2014;65:634–640. doi:10.1177/0003319713513143
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Korean. Korean Circ J. 2010;40:314–320. doi:10.4070/kcj.2010.40.7.314
   PubMedGoogle Scholar
• Canepa M, Viazzi F, Strait JB, et al. Longitudinal association between serum uric acid and arterial stiffness: results from the Baltimore longitudinal study of aging. Hypertension. 2017;69(2):228–235. doi:10.1161/HYPERTENSIONAHA.116.08114
   PubMed Web of Science ®Google Scholar
• Nagano S, Takahashi M, Miyai N, et al. Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects. Hypertension. 2017;40:620–624. doi:10.1038/hr.2017.10
   Web of Science ®Google Scholar
• Ding X, Ye P, Wang X, et al. Peripheral arterial stiffness is associated with basal plasma uric acid: a prospective cohort study. Saudi J Biol Sci. 2017;24:574–581. doi:10.1016/j.sjbs.2017.01.028
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Nakagawa T, Mazzali M, Johnson RJ. Uric acid and hypertension. Curr Hypertens Rep. 2006;8:111–115. doi:10.1007/s11906-006-0005-z
   PubMed Web of Science ®Google Scholar
• Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–252. doi:10.1161/01.HYP.0000085858.66548.59
   PubMed Web of Science ®Google Scholar
• Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse (Basel). 2016;3:242–252. doi:10.1159/000443769
   PubMedGoogle Scholar
• Mazzali M, Hugues J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–1106. doi:10.1161/hy1101.092839
   PubMed Web of Science ®Google Scholar
• Tsai WC, Huang YY, Lin CC, et al. Uric acid is an independent predictor of arterial stiffness in hypertensive patients. Heart Vessels. 2009;24(5):371–375. doi:10.1007/s00380-008-1127-9
   PubMed Web of Science ®Google Scholar
• Ramirez AJ, Christen AI, Sanchez RA. Serum acid uric elevation is associated to arterial stiffness in hypertension patients with metabolic disturbances. Curr Hypertens Rev. 2018;14(2):154–160. doi:10.2174/1573402114666180413143312
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Vyssoulis G, et al. Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension. Am J Hypertens. 2011;24:33–39. doi:10.1038/ajh.2010.111
   PubMed Web of Science ®Google Scholar
• Hsu P-F, Chuang S-Y, Cheng H-M, et al. Associations of serum uric acid levels with arterial wave reflections and central systolic blood pressure. Int J Cardiol. 2013;168(3):2057–2063. doi:10.1016/j.ijcard.2013.01.164
   PubMed Web of Science ®Google Scholar
• Mulè G, Riccobene R, Castiglia A, et al. Relationship between mild hyperuricemia and aortic stiffness in untreated hypertensive patients. Nutr Metab Cardiovasc Dis. 2014;24:744–750. doi:10.1016/j.numecd.2014.01.014
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Chatzis D, Vezali E, et al. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens. 2005;19:211–217. doi:10.1038/sj.jhh.1001810
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Kyvelou S, Dimitriadis K, et al. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Human Hypertens. 2011;25:554–559. doi:10.1038/jhh.2010.98
   PubMed Web of Science ®Google Scholar
• Saladini F, Benetti E, Fania C, et al. Association between uric acid, metabolic variables and arterial stiffness in the early phase of hypertension. J Hypertens. 2016; e208. doi:10.1097/01.hjh.0000467906.49825.ad.
   Web of Science ®Google Scholar
• Cipolli JAA, Ferreira-Sae MC, Martins RP, et al. Relationship between serum uric acid and internal carotid resistive index in hypertensive women: a cross-sectional study. BMC Cardiovasc Disord. 2012;12:52. doi:10.1186/1471-2261-12-52
   PubMed Web of Science ®Google Scholar
• Frauchiger B, Schmid HP, Roedel C, Moosmann P, Staub D. Comparison of carotid arterial resistive indices with intima-media thickness as sonographic markers of atherosclerosis. Stroke. 2001;32:836–841. doi:10.1161/01.STR.32.4.836
   PubMed Web of Science ®Google Scholar
• Gomez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, et al.; Vasorisk group. Relationship between uric acid and vascular structure and function in hypertensive patients and sex-related differences. Am J Hypertens. 2013;26(5):599–607. doi:10.1093/ajh/hps097.
   PubMed Web of Science ®Google Scholar
• Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005;45:34–38. doi:10.1161/01.HYP.0000150783.79172.bb
   PubMed Web of Science ®Google Scholar
• Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33. doi:10.1161/01.HYP.0000150784.92944.9a
   PubMed Web of Science ®Google Scholar
• Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48:1031–1036. doi:10.1161/01.HYP.0000248752.08807.4c
   PubMed Web of Science ®Google Scholar
• Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48:1037–1042. doi:10.1161/01.HYP.0000249768.26560.66
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–530. doi:10.1023/a:1024600905574
   PubMed Web of Science ®Google Scholar
• Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–480. doi:10.1161/01.HYP.0000091371.53502.D3
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five year Japanese cohort study. Hypertension. 2017;69:1036–1044. doi:10.1161/HYPERTENSIONAHA.116.08998
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71:78–86. doi:10.1161/HYPERTENSIONAHA.117.10370
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Shiina K, Vlachopoulos C, et al. Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension. Hypertension. 2018;72:739–745. doi:10.1161/HYPERTENSIONAHA.118.11390
   PubMed Web of Science ®Google Scholar
• Tanaka A, Kawaguchi A, Tomiyama H, et al. Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension. Int J Cardiol. 2018;272:308–313. doi:10.1016/j.ijcard.2018.06.017
   PubMed Web of Science ®Google Scholar
• Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–1742. doi:10.2337/dc09-0288
   PubMed Web of Science ®Google Scholar
• Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8:e56864. doi:10.1371/journal.pone.0056864
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu J, Gao L, et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One. 2013;8(10):e78206. doi:10.1371/journal.pone.0078206
   PubMed Web of Science ®Google Scholar
• Rizzo M, Obradovic M, Labudovic-Borovic M, et al. Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol. 2014;12:572–585. doi:10.2174/1570161111999131205160756
   PubMed Web of Science ®Google Scholar
• Tsushima Y, Nishizawa H, Tochinoet Y, et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem. 2013;288:27138–27149. doi:10.1074/jbc.M113.485094
   PubMed Web of Science ®Google Scholar
• Stehouwer CDA, Henry RMA, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008;51:527–539. doi:10.1007/s00125-007-0918-3
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiang G, Xiang L, Sun H. Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus. J Endocrinol Investig. 2014;37(5):441–447. doi:10.1007/s40618-013-0034-9
   PubMed Web of Science ®Google Scholar
• Sun N, Zhang Y, Tian J-L WH. Relationship between uric acid and arterial stiffness in the elderly with metabolic syndrome components. Chin Med J (Engl). 2013;126(16):3097–3102. doi:10.3760/cma.j.issn.0366-6999.20130215
   PubMed Web of Science ®Google Scholar
• Wijnands JM, Boonen A, van Sloten TT, et al. Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40–75 years without and with type 2 diabetes mellitus: the Maastricht Study. J Hypertens. 2015;33(8):1642–1650. doi:10.1097/HJH.0000000000000593
   PubMed Web of Science ®Google Scholar
• Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45:494–501. doi:10.1053/j.ajkd.2004.11.011
   PubMed Web of Science ®Google Scholar
• Nemcsik J, Kiss I, Tisler A. Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease. World J Nephrol. 2012;1(1):25–34. doi:10.5527/wjn.v1.i1.25
   PubMedGoogle Scholar
• Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82:388–400. doi:10.1038/ki.2012.131
   PubMed Web of Science ®Google Scholar
• Xia X, He F, Wu X, Peng F, Huang F, Yu X. Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis. Am J Kidney Dis. 2014;64:257–264. doi:10.1053/j.ajkd.2013.08.027
   PubMed Web of Science ®Google Scholar
• Bellomo G. Asymptomatic hyperuricemia following renal transplantation. World J Nephrol. 2015;4(3):324–329. doi:10.5527/wjn.v4.i3.324.
   PubMedGoogle Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803. doi:10.1053/j.ajkd.2008.12.021
   PubMed Web of Science ®Google Scholar
• Elsurer R, Afsar B. Serum uric acid and arterial stiffness in hypertensive chronic kidney disease patients: sex-specific variations. Blood Press Monit. 2014;19:271–279. doi:10.1097/MBP.0000000000000056
   PubMed Web of Science ®Google Scholar
• Liu X, Wu J, Wu H, et al. Association of serum uric acid with arterial stiffness in peritoneal dialysis patients. Kidney Blood Res. 2018;43:1451–1458. doi:10.1159/000493659
   PubMed Web of Science ®Google Scholar
• Bauer F, Pagonas N, Seibert FS, et al. Serum uric acid and arterial function after renal transplantation. Ann Transplant. 2017;14(22):431–439. doi:10.12659/aot.901657
   Web of Science ®Google Scholar
• Tanindi A, Erkan AF, Alhan A, Tör HF. Arterial stiffness and central arterial wave reflection are associated with serum uric acid, total bilirubin, and neutrophil-to-lymphocyte ratio in patients with coronary artery disease. Anatol J Cardiol. 2015;15:396–403. doi:10.5152/akd.2014.5447
   PubMed Web of Science ®Google Scholar
• Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJF. The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. Atherosclerosis. 2000;200(2):374–379. doi:10.1016/j.atherosclerosis.2007.12.023
   Web of Science ®Google Scholar
• Park JS, Kang S, Ahn CW, Cha BS, Kim KR, Lee HC. Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women. Maturitas. 2012;73:344–348. doi:10.1016/j.maturitas.2012.09.009
   PubMed Web of Science ®Google Scholar
• Lee H, Jung Y-H, Kwon Y-J, Park B. Uric acid level has a J-shaped association with arterial stiffness in Korean postmenopausal women. Korean J Fam Med. 2017;38:333–337. doi:10.4082/kjfm.2017.38.6.333
   PubMed Web of Science ®Google Scholar
• McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics. 2014;24(9):464–476. doi:10.1097/FPC.0000000000000058
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Alperovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74:836–842. doi:10.1136/annrheumdis-2012-202972
   PubMed Web of Science ®Google Scholar
• MacIsaac RL, Salatzki J, Higgins P, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016;67:535–540. doi:10.1161/HYPERTENSIONAHA.115.06344
   PubMed Web of Science ®Google Scholar
• Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87:229–234. doi:10.1136/heart.87.3.229
   PubMed Web of Science ®Google Scholar
• Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009;48:804–806. doi:10.1093/rheumatology/kep069
   PubMed Web of Science ®Google Scholar
• Bredemeier M, Lopes LM, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trial. BMC Cardiovasc Disord. 2018;18:24. doi:10.1186/s12872-018-0757-9
   PubMed Web of Science ®Google Scholar
• Deng G, Qiu Z, Li D, Fang Y, Zhang S. Effects of allopurinol on arterial stiffness: a meta-analysis of randomized controlled trials. Med Sci Monit. 2016;22:1389–1397. doi:10.12659/msm.898370
   PubMed Web of Science ®Google Scholar
• Alem MM, Alshehri AM, Cahusac PMB, Walters MR. Effect of xanthine oxidase inhibition on arterial stiffness in patients with chronic heart failure. Clin Med Insights Cardiol. 2018;12:1–10. doi:10.1177/1179546818779584
   Web of Science ®Google Scholar
• George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–2516. doi:10.1161/CIRCULATIONAHA.106.651117
   PubMed Web of Science ®Google Scholar
• Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217–226. doi:10.1111/j.1755-5922.2011.00277
   PubMed Web of Science ®Google Scholar
• Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011;58:820–828. doi:10.1016/j.jacc.2010.12.052
   PubMed Web of Science ®Google Scholar
• Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227–1233. doi:10.1007/s11255-007-9253-3
   PubMed Web of Science ®Google Scholar
• Ng KP, Stringer SJ, Jesky MD, et al. Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross sectional study. PLoS One. 2014;9(3):e91961. doi:10.1371/journal.pone.0091961
   PubMed Web of Science ®Google Scholar
• Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:435–442. doi:10.1111/j.1751-7176.2012.00701.x
   PubMed Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: Phase 3 clinical study. J Clin Rheumatol. 2011;17:S13–S18. doi:10.1097/RHU.0b013e31821d36cc
   PubMed Web of Science ®Google Scholar
• Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med. 2011;51:179–184. doi:10.1016/j.freeradbiomed.2011.04.004
   PubMed Web of Science ®Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU‑FLASH Trial). Circ J. 2013;77:2043–2049. doi:10.1253/circj.cj-13-0082
   PubMed Web of Science ®Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU‑FLASH trial for CKD). J Cardiol. 2015;66:298–303. doi:10.1016/j.jjcc.2014.12.017
   PubMed Web of Science ®Google Scholar
• Tausche AK, Christoph M, Forkmann M, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int. 2014;34(1):101–109. doi:10.1007/s00296-013-2857-2
   PubMed Web of Science ®Google Scholar
• Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology. 2017;56:1144–1153. doi:10.1093/rheumatology/kex065
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al.; for the CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200–1210. doi:10.1056/NEJMoa1710895
   PubMed Web of Science ®Google Scholar
• Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamari L. Febuxostat and cardiovascular events: a systematic review and meta-analysis. Int J Rheumatol. 2019;2019:1–10. doi:10.1155/2019/1076189
   Web of Science ®Google Scholar
• Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart J. 2018;70(6):915–921. doi:10.1016/j.ihj.2018.08.022
   PubMedGoogle Scholar
• Sanchez RA, Sanchez MJ, Ramirez AJ. Canagliflozin ameliorates arterial stiffness by reducing serum uric acid in type 2 diabetic patients. Diabetes. 2018;67(Supplement 1):1216–P. doi:10.2337/db18-1216-P
   PubMed Web of Science ®Google Scholar
• Bekki M, Tahara N, Tahara A, et al. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study. Curr Vasc Pharmacol. 2018. doi:10.2174/1570161116666180515154555
   Web of Science ®Google Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes, Obes Metab. 2015;17:1180–1193. doi:10.1111/dom.12572
   PubMed Web of Science ®Google Scholar
• Aroor AR, Das NA, Carpenter AJ, et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018;17:108. doi:10.1186/s12933-018-0750-8
   PubMed Web of Science ®Google Scholar
• Striepe K, Jumar A, Ott C, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167–1169. doi:10.1161/CIRCULATIONAHA.117.029529
   PubMed Web of Science ®Google Scholar
• Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018;13(2):84–91. doi:10.2174/1574886313666180226103408
   PubMed Web of Science ®Google Scholar
• Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007;50(12):2572–2579. doi:10.1007/s00125-007-0817-7
   PubMed Web of Science ®Google Scholar